PDCD1 and neoplasm: Inspiringly, the combination of SCT-15 with anti-PD1 therapy can synergistically enhance the anti-tumor properties resulting in tumor regression in MC38 CRC and A20 lymphoma syngeneic models, with mice remaining tumor-free long after treatment has ceased (84).